Results 21 to 30 of about 8,947 (130)

Valganciclovir is not associated with decreased EBV infection rate in pediatric kidney transplantation

Frontiers in Pediatrics, 2023
IntroductionPrimary infection or reactivation of Epstein-Barr Virus (EBV) is a significant cause of morbidity and mortality in pediatric kidney transplantation.
Elodie Cheyssac, Hamidou Savadogo, Nathan Lagoutte, Véronique Baudouin, Marina Charbit, Robert Novo, Anne-Laure Sellier-Leclerc, Marc Fila, Stéphane Decramer, Elodie Merieau, Ariane Zaloszyc, Jérôme Harambat, Gwenaelle Roussey   +12 more
doaj   +1 more source

Efficacy and Safety of Antiviral Agents in Preventing Allograft Rejection Following CMV Prophylaxis in High-Risk Kidney Transplantation: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Frontiers in Cellular and Infection Microbiology, 2022
Many antiviral agents have been studied in clinical trials for allograft rejection prevention following cytomegalovirus (CMV) prophylaxis in high-risk kidney transplant patients. However, data on the most effective and safest treatment are lacking.
Narisa Ruenroengbun, Tunlanut Sapankaew, Kamolpat Chaiyakittisopon, Pakpoom Phoompoung, Thundon Ngamprasertchai   +4 more
doaj   +1 more source

Accuracy of valganciclovir dosing following kidney transplantation and its impact on clinical outcomes

Frontiers in Nephrology
Valganciclovir is widely used as prophylaxis against cytomegalovirus (CMV) infection following solid organ transplantation. However, valganciclovir requires dose adjustment based on kidney function.
Jessica Forsyth, David Randall, Raj Thuraisingham   +2 more
doaj   +1 more source

Letermovir for Cytomegalovirus Prophylaxis in Lung Transplant Patients with Valganciclovir-Induced Leukopenia

Transplantology, 2021
Cytomegalovirus (CMV) prophylaxis with valganciclovir is the standard of practice in most transplant centers, but treatment-related leukopenia can limit valganciclovir’s use.
Arindam Singha, Pamela K. Burcham, April Logan, Zeinab El Boghdadly, Molly M. Howsare, David R. Nunley, Mark E. Lustberg, Brian C. Keller   +7 more
doaj   +1 more source

Transient Azoospermia Induced by Valganciclovir Treatment for Cytomegalovirus Infection in a Reproductive Male After Kidney Transplant: A Case Report

IJU Case Reports
Introduction Spermatogenic dysfunction is a side effect of valganciclovir, which is commonly used to treat cytomegalovirus infections. Here, we report the case of a reproductive man who underwent kidney transplantation and was diagnosed with azoospermia ...
Kosuke Mieda, Shunta Hori, Mitsuru Tomizawa, Kuniaki Inoue, Tatsuo Yoneda, Yuji Nitta, Yasushi Nakai, Makito Miyake, Nobumichi Tanaka, Kiyohide Fujimoto   +9 more
doaj   +1 more source

Improving Medication Safety Following Neonatal Discharge: A Feasibility Study of a Parent Medication Education Intervention in Ireland

Acta Paediatrica, EarlyView.
ABSTRACT Aim Neonates discharged home on medications remain at risk of medication errors. The PADDINGToN programme previously developed parent co‐designed resources to support safer medication administration following discharge. The aim of this study, PADDINGToN‐2, is to evaluate the feasibility of recruiting and retaining parents in a study assessing ...
S. Giva, B. Cleary, F. Gaffney, L. Bracken, A. Gill, C. Sutton, J. Clark, V. Gray, N. McCallion, F. O'Brien   +9 more
wiley   +1 more source

Experience of Using the Antiviral Therapy of Generalized Congenital Cytomegalovirus Infection

Детские инфекции (Москва), 2016
The article presents the results of observation and treatment with ganciclovir and oral valganciclovir form of a premature infant with congenital generalized symptomatic cytomegalovirus infection (CMVI) involving pathology of CNS, cholangitis ...
G. V. Petrova, V. I. Shakhgildyan, E. A. Chistozvonova, T. A. Pugacheva, N. V. Turkot, M. V. Egorova, O. U. Sautenko, I. B. Astasheva, O. V. Romanova, N. V. Kostycheva, T. A. Grigorieva, M. G. Kulagina   +11 more
doaj   +1 more source

Optimizing Pneumocystis jirovecii Prophylaxis in Immunocompromised Patients: Defining the Clinical Role of Atovaquone

Transplant Infectious Disease, EarlyView.
In a retrospective cohort study of 149 patients receiving atovaquone for PJP prophylaxis, increased usage was related to broader indications, uptake in new patient groups, difficulty tolerating or accessing alternatives, and longer durations used per patient.
To N. Pham, Kelly A. Cairns, Adithi Ramachandra, Susan G. Poole, Carmela E. Corallo, Bradley J. Gardiner   +5 more
wiley   +1 more source

Secondary Hemophagocytic Lymphohistiocytosis Complicated by Mucormycosis Following Liver Transplantation for Cryptogenic Acute Liver Failure: A Case Report

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT HLH must be suspected in liver transplant patients who exhibit fever, cytopenia, hyperferritinemia, and dysfunction of the graft. HLH‐2004 guidelines and H‐score assessment early on will aid in early diagnosis and management, although prognosis remains poor when there are opportunistic infections.
Saif Ali Malik, Muhammad Hassaan Javaid, Syed Sibt E Haider, Hajirah Ghairat, AbuBakar Hafeez Bhatti, Hasibullah Aminpoor   +5 more
wiley   +1 more source

Clinical‐Stage Nanatinostat Triggers Productive Epstein‐Barr Virus Lytic Replication

Journal of Medical Virology, Volume 98, Issue 8, August 2026.
ABSTRACT A phase 1b/2 study of the all‐oral “kick‐and‐kill” combo nanatinostat + valganciclovir (nana‐val) showed a ~40% overall response rate in patients with relapsed/refractory Epstein‐Barr virus (EBV)‐associated lymphomas. Despite the promising results in these difficult‐to‐treat cancers, there is little known about the effects of nanatinostat on ...
Ibukun A. Akinyemi, Travis M. Zeigler, Griffin H. Willman, Devshree Patel, Ayman El‐Guindy, Michael T. McIntosh, Sumita Bhaduri‐McIntosh   +6 more
wiley   +1 more source